SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
Abstract
Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium–glucose co-transporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Faris, R. F., Flather, M., Purcell, H., Poole-Wilson, P. A., & Coats, A. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003838.pub3 · Cited by 156
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 9×
“In EMPA-REG OUTCOME, there were no differences in sodium, potassium, calcium, magnesium and phosphate between groups [23].”
BackgroundResultInfluentialChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“Reduction in fat body mass due to calorie loss [23, 36] could be another protective mechanism of SGLT-2 inhibitors since obesity is a known cardiovascular risk factor [57].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 5×
“Liraglutide in the LEADER trial showed a non-significant reduction, whereas semaglutide in SUSTAIN-6 showed a nonsignificant increase in heart failure hospitalizations [25, 26].”
BackgroundResultInfluentialBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 9×
“This is of utmost importance since both major trials examining the effect of combined RAS blockade in DKD (i.e. the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopri…”
ResultInfluentialWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000 · cited 3×
“The presence of hypertension increases cardiovascular risk by almost four times in patients with DM, whereas the presence of DM almost triples the risk of cardiovascular disease at any level of systolic blood pressure (SBP) [5, 6].”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 3×
“However, in SUSTAIN-6, the frequency of gall bladder disorders was not different between semaglutide and placebo [26].”
BackgroundResultDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 8×
“This is of utmost importance since both major trials examining the effect of combined RAS blockade in DKD (i.e. the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopri…”
ResultInfluentialThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 3×
“The presence of hypertension increases cardiovascular risk by almost four times in patients with DM, whereas the presence of DM almost triples the risk of cardiovascular disease at any level of systolic blood pressure (SBP) [5, 6].”
BackgroundInfluentialEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 5×
“In an analysis of renal outcomes of the EMPA-REG OUTCOME [28], patients treated with empagliflozin had a reduction in the pre-specified composite outcome of progression to macroalbuminuria, doubling of serum creatinine (SCr), initiation of renal replacement therapy or death from renal disease (HR 0.”
BackgroundMethodResultInfluentialDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“A multifactorial intervention in patients with type 2 DM, including improving glycaemic control, treating BP with RAS blockers, using statins and implementing lifestyle interventions is able, among other things, to slow CKD progression [193, 194].”
BackgroundObesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093 · cited 1×
“Reduction in fat body mass due to calorie loss [23, 36] could be another protective mechanism of SGLT-2 inhibitors since obesity is a known cardiovascular risk factor [57].”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“64), with an identical effect in patients with and without atherosclerotic cardiovascular disease [40].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“The major adverse effects of GLP-1 receptor agonists are gastrointestinal including nausea, vomiting and diarrhoea, all of which may also contribute to reduced calorie intake [131, 133, 134].”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“In the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial, 6068 patients with type 2 DM with either a MI or hospitalized for unstable angina in the preceding 180 days were randomized to receive either lixisenatide 10–20 lg or placebo [115].”
MethodResultThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“In addition to weight loss, proposed mechanisms include GLP-1-mediated release of atrial natriuretic peptide by cardiomyocytes leading to vasodilatation, improved endothelial function and natriuresis [124, 136, 137].”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 2×
“Outcome trials with liraglutide [25, 109], semaglutide [26], extended-release exenatide [110] and, recently, albiglutide [27] have clearly shown reductions in cardiovascular events that were similar across eGFR subgroups.”
BackgroundHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · cited 6×
“Although renal outcomes data from the HARMONY OUTCOMES study have not yet been published, safety data suggest that there were no differences in eGFR between groups at 16 months (HR 0.43, 95% CI 1.26 to 0.41 mL/min/1.73 m2) [27].”
BackgroundMethodInfluentialAdler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816 · cited 1×
“Microalbuminuria (A2 albuminuria category) is one of the earliest detectable manifestations of CKD in DM, with a prevalence of 25% after 10 years and an annual rate of progression to macroalbuminuria (A3 albuminuria category) around 3% [9].”
BackgroundMulti-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,610 · cited 2×
“The heart is the organ with the highest energy expenditure and 70% originates from fatty acid oxidation [69].”
BackgroundCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 8×
“In individuals with genetic defects in SGLT-2 and in diabetics not on RAS blockade, SGLT-2 inhibition resulted in RAS activation as evidenced by serum renin, angiotensin II and aldosterone levels, although renin increase with SGLT-2 inhibitors is much smaller than that with classical diuretics [61, 63].”
BackgroundInfluentialCardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319 · cited 2×
“the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopril versus losartan alone [77] were prematurely stopped due to increased risk of complications, including hypotens…”
BackgroundLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253 · cited 4×
“There were no differences in the rates of renal adverse events (including AKI) between the two groups [109].”
BackgroundInfluentialDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“In the SCALE Diabetes Randomized Trial, a maximum daily dose of 3 mg of liraglutide showed an 18% reduction in albuminuria compared with placebo [164].”
BackgroundCombined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169 · cited 1×
“the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopril versus losartan alone [77] were prematurely stopped due to increased risk of complications, including hypotens…”
BackgroundWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975 · cited 1×
“Post hoc analyses of the RENAAL and IDNT trials suggested that the magnitude of proteinuria reduction during follow-up was predictive of the primary outcome [79, 80].”
MethodPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Early concerns about increased pancreatitis [177, 178] and medullary thyroid cancer risk [177, 179] with GLP-1 receptor agonists have not been substantiated in the large outcome studies [25–27, 115], nor in recent meta-analyses of RCTs [180, 181].”
BackgroundCardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Hunt, B., Castillo, M., & Gunawardhana, L. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710895 · Cited by 909 · cited 1×
“Lowering uric acid has also been proposed, but recent trials of urate-lowering therapy observed higher mortality in patients achieving lower serum urate [45, 46].”
ResultFitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“In the setting of acute MI, injection of GLP-1 receptor agonist improved left ventricular function in patients with severe systolic dysfunction after successful primary angioplasty [159].”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“The mechanism for this is currently unknown, but may be mediated by direct actions of these drugs on sinoatrial node [185] or activation of the sympathetic nervous system [186].”
BackgroundThe hyperfiltration theory: A paradigm shift in nephrology
Brenner, B. M., Lawler, E. V., & Mackenzie, H. S. (1996) · Kidney International · doi:10.1038/ki.1996.265 · Cited by 868 · cited 1×
“As patients with proteinuric CKD commonly progress to ESRD via single-nephron hyperfiltration [200], this mode of action of SGLT-2 inhibitors offers a unique opportunity for nephroprotection.”
BackgroundDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823 · cited 1×
“This effect is typical of the initial, functional ‘dip’ in eGFR that resembles the effect of RAS blockers, is associated with long-term nephroprotection and is reversible upon discontinuation of the drug [100].”
BackgroundKosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813 · cited 1×
“In addition to the above, CVD-REAL is a real-world observational study of 309 056 patients with DM, 87% of whom had no history of cardiovascular disease [41].”
BackgroundHostetter, T. H., Rennke, H. G., & Brenner, B. M. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90490-9 · Cited by 796 · cited 1×
“Hyperfiltration and glomerular hypertension are common features of early diabetic nephropathy and are known factors promoting initiation and progression of all proteinuric nephropathies, through increased filtration of many molecules, including albumin [93, 94].”
BackgroundRahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“In mediation analysis, these were key determinants of beneficial cardiovascular outcomes [64].”
BackgroundMargulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706 · cited 2×
“In the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) trial 300 patients with heart failure and reduced ejection fraction were randomized to liraglutide or placebo [157].”
BackgroundMethodInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694 · cited 4×
“73 m(2) [196], is beyond the scope of this document; the reader is referred to a previous Clinical Practice Guideline from ERA-EDTA [198].”
BackgroundInfluentialBonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“SGLT-2 inhibition in pancreatic alpha-cells triggers glucagon secretion [66].”
BackgroundThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 2×
“In addition to weight loss, proposed mechanisms include GLP-1-mediated release of atrial natriuretic peptide by cardiomyocytes leading to vasodilatation, improved endothelial function and natriuresis [124, 136, 137].”
BackgroundBaartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 1×
“However, 5-week treatment with GLP-1 improved left ventricular function, functional status and quality of life in patients with severe heart failure, benefits were seen in both diabetic and non-diabetic patients [158].”
BackgroundKohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 1×
“73 m(2) over the first 2–3 weeks [92, 99], attributed to hypovolaemia and considered a possible side effect.”
BackgroundTuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648 · cited 10×
“This is of utmost importance since both major trials examining the effect of combined RAS blockade in DKD (i.e. the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopri…”
BackgroundInfluentialPerkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637 · cited 28×
“The present consensus report examined recent evidence on the use of SGLT-2 inhibitors and GLP-1 receptor agonists in diabetic patients with CKD, that is with eGFR <60 mL/ min/1.73 m2 or with eGFR >60 mL/min/1.73 m2 and microor microalbuminuria and those without CKD. Evidence from EMPA-REG OUTCOME and CANVAS studies su…”
BackgroundInfluentialUthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · cited 9×
“Current guidelines for patients with heart failure indicate diuretics to reduce the signs/symptoms of congestion as their effects on mortality have not been studied in large RCTs [52].”
BackgroundInfluentialCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · cited 1×
“In addition to weight loss, proposed mechanisms include GLP-1-mediated release of atrial natriuretic peptide by cardiomyocytes leading to vasodilatation, improved endothelial function and natriuresis [124, 136, 137].”
Backgroundvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“The major adverse effects of GLP-1 receptor agonists are gastrointestinal including nausea, vomiting and diarrhoea, all of which may also contribute to reduced calorie intake [131, 133, 134].”
BackgroundThe sodium/glucose cotransport family SLC5
Wright, E. M., & Turk, E. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1202-0 · Cited by 537 · cited 1×
“When plasma glucose concentration exceeds 200–250 mg/dL, the cotransporters approach saturation, thus excreting excessive filtered glucose [82].”
Background(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.46 · Cited by 521
Nikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493 · cited 1×
“SGLT-2 is a high-capacity/ low-affinity transporter found mainly in the S1-segment, responsible for 90% of glucose reabsorption, while SGLT-1 is a low-capacity/high-affinity transporter in the S2/S3 segment of the PCT, reabsorbing the remaining 10% [20, 81].”
BackgroundCanagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Is Glycemic Control Improving in U.S. Adults?
Hoerger, T. J., Segel, J. E., Gregg, E. W., & Saaddine, J. B. (2008) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477
Introduction: Standards of Medical Care in Diabetes—2018
(2018) · Diabetes Care · doi:10.2337/dc18-sint01 · Cited by 472
Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.028268 · Cited by 469 · cited 1×
“73 m(2) or in further eGFR subgroups [35, 37].”
BackgroundSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“Early concerns about increased pancreatitis [177, 178] and medullary thyroid cancer risk [177, 179] with GLP-1 receptor agonists have not been substantiated in the large outcome studies [25–27, 115], nor in recent meta-analyses of RCTs [180, 181].”
BackgroundLytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
Vallon, V., Mühlbauer, B., & Osswald, H. (2006) · Physiological Reviews · doi:10.1152/physrev.00031.2005 · Cited by 448 · cited 1×
“The macula densa senses the increased chloride availability and restores the tubuloglomerular feedback by promoting afferent arteriole vasoconstriction, thus decreasing intraglomerular pressure and GFR; this is a physiological mechanism aiming to avoid excess sodium loss in cases of proximal tubular damage (Figure 2)…”
BackgroundGlucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · cited 3×
“Under physiological conditions, GLP-1 agonists have either no effect or induce glomerular hyperfiltration by reducing afferent arteriolar resistance [126, 138, 171].”
BackgroundEffects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Cooney, M. T., Vartiainen, E., Laakitainen, T., Juolevi, A., Dudina, A., & Graham, I. M. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.12.029 · Cited by 416 · cited 1×
“GLP-1 receptor agonists induce an increase in heart rate [182] that theoretically could represent a safety concern [183, 184].”
BackgroundGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · cited 1×
“Under physiological conditions, GLP-1 agonists have either no effect or induce glomerular hyperfiltration by reducing afferent arteriolar resistance [126, 138, 171].”
BackgroundZheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., & Meeran, K. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 403 · cited 3×
“A meta-analysis of 236 trials enrolling 176 310 patients with type 2 DM demonstrated that SGLT-2 inhibitors and GLP-1 receptor agonists were associated with lower all-cause and cardiovascular mortality compared with DPP-4 inhibitors [121].”
BackgroundPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 1×
“In addition, pre-clinical studies have shown that GLP-1 receptor agonists reduce proteinuria and glomerular sclerosis associated with protection from endothelial injury and reductions in oxidative stress and inflammation in a glucose-independent manner [168, 169].”
BackgroundCherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383 · cited 2×
“An exploratory analysis on this effect [74] showed that after cessation of treatment for about 35 days, UACR was lower with empagliflozin compared with placebo in patients with baseline microalbuminuria ( 22%; P1⁄4 0.”
BackgroundResultAtkins, R. C., Briganti, E. M., Lewis, J. B., Hunsicker, L. G., Braden, G., Champion de Crespigny, P. J., DeFerrari, G., Drury, P., Locatelli, F., Wiegmann, T. B., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.019 · Cited by 367 · cited 1×
“Post hoc analyses of the RENAAL and IDNT trials suggested that the magnitude of proteinuria reduction during follow-up was predictive of the primary outcome [79, 80].”
MethodCefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 1×
“These effects of SGLT-2 inhibitors on reduction of glomerular hyperfiltration and intraglomerular pressure are supported by the EMPA-REG OUTCOME and CANVAS trials, as well as several other studies, showing decrease in urine albumin excretion [97, 98].”
ResultMoser, M., & Hebert, P. R. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00606-0 · Cited by 345 · cited 1×
“However, data from the major outcome RCTs in hypertension treatment suggest that the endpoint mostly reduced with active treatment was congestive heart failure and not stroke [50], in a timeline relevant to SGLT-2 inhibitor trials.”
BackgroundTerami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341 · cited 1×
“Animal studies showed that SGLT-2 inhibitors can slow down the progression of diabetic nephropathy and ameliorate the associated histological features (mesangial matrix accumulation, glomerular enlargement and interstitial fibrosis) [95].”
BackgroundSodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · cited 1×
“It occurs more frequently in individuals with type 1 DM treated off-label with these agents [106].”
BackgroundJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · cited 1×
“This body weight decrease is associated with reduction in total fat, rather than in lean tissue mass [129, 130].”
BackgroundLiraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311 · cited 1×
“The major adverse effects of GLP-1 receptor agonists are gastrointestinal including nausea, vomiting and diarrhoea, all of which may also contribute to reduced calorie intake [131, 133, 134].”
BackgroundFranse, L. V., Pahor, M., Di Bari, M., Somes, G. W., Cushman, W. C., & Applegate, W. B. (2000) · Hypertension · doi:10.1161/01.hyp.35.5.1025 · Cited by 306 · cited 1×
“Side effects of thiazide and loop diuretics, mainly hypokalaemia, were previously suggested to prevent the appearance of the full cardiovascular benefit of these drugs [54, 55].”
BackgroundSun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 1×
“A previous meta-analysis showed SBP reductions with liraglutide and albuglutide, albeit non-significantly with exenatide and dulaglutide [135].”
MethodUpdate of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013
IDF Diabetes Atlas Group (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.037 · Cited by 296
How can we achieve global equity in provision of renal replacement therapy?
White, S. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.07.041715 · Cited by 291 · cited 1×
“Diabetes is a leading cause of CKD, accounting for 30–50% of incident end-stage renal disease (ESRD) in the western world [8].”
BackgroundCardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286 · cited 1×
“Lowering uric acid has also been proposed, but recent trials of urate-lowering therapy observed higher mortality in patients achieving lower serum urate [45, 46].”
ResultExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284 · cited 1×
“Liraglutide reduced plasma concentrations of both plasminogen activator inhibitor-1 and C-reactive protein in patients with DM [137]; exenatide exerted anti-inflammatory effects in diabetic patients without micro- or macrovascular complications [155].”
BackgroundCrajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278
Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., & Mather, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054442 · Cited by 277
Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275 · cited 1×
“Proposed mechanisms include reductions in post-prandial chylomicron synthesis and reduced triglyceride absorption [147, 148], as well as increased post-prandial insulin production and reduction in glucagon release leading to inhibition of adipose tissue lipolysis [149, 150].”
BackgroundNeuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035901 · Cited by 257
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234 · cited 1×
“72 m(2) and UACR >300 to 5000 mg/g) [188] with projected duration of 5.”
BackgroundSun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232 · cited 1×
“Studies consistently demonstrate beneficial effects of GLP-1 receptor agonists on lipid profiles [132].”
BackgroundO'Neill, J., Fasching, A., Pihl, L., Patinha, D., Franzén, S., & Palm, F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00689.2014 · Cited by 232 · cited 1×
“Other mechanisms involved could be the improvement of renal hypoxia observed in diabetic kidneys, due to reduction of activity and, thus, energy requirements of SGLT-2 [85].”
BackgroundSkov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228
Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Heart Rate as a Risk Factor for Cardiovascular Disease
Perret-Guillaume, C., Joly, L., & Benetos, A. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.05.003 · Cited by 222 · cited 1×
“GLP-1 receptor agonists induce an increase in heart rate [182] that theoretically could represent a safety concern [183, 184].”
BackgroundTang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
The clinical significance of hyperfiltration in diabetes
Jerums, G., Premaratne, E., Panagiotopoulos, S., & MacIsaac, R. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1794-9 · Cited by 198 · cited 1×
“Hyperfiltration and glomerular hypertension are common features of early diabetic nephropathy and are known factors promoting initiation and progression of all proteinuric nephropathies, through increased filtration of many molecules, including albumin [93, 94].”
BackgroundFaris, R. F., Flather, M., Purcell, H., Poole-Wilson, P. A., & Coats, A. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003838.pub4 · Cited by 195
Freitas, H. S., Anhê, G. F., Melo, K. F. S., Okamoto, M. M., Oliveira-Souza, M., Bordin, S., & Machado, U. F. (2008) · Endocrinology · doi:10.1210/en.2007-1088 · Cited by 192 · cited 1×
“Animals and humans with DM express higher number of renal SGLT-2 co-transporters than healthy individuals, leading to 20% increase in glucose reabsorption [89, 90], as an attempt by the body to conserve glucose.”
BackgroundGuideline Development Group., Bilo, H. J. G., Coentrão, L., Couchoud, C., Covic, A. C., SUTTER, J. D., Drechsler, C., Gnudi, L., Goldsmith, D. J. A., Heaf, J. G., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv100 · Cited by 190
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa, B. C., & Inzucchi, S. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4663-6 · Cited by 190 · cited 3×
“Volume depletion with orthostatic hypotension and decrease in bone mineral density with canagliflozin are between the proposed mechanisms [102], but additional data are needed.”
BackgroundAcute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
Nadkarni, G. N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., Saha, A., Ferket, B., Grams, M. E., & Coca, S. G. (2017) · Diabetes Care · doi:10.2337/dc17-1011 · Cited by 188 · cited 1×
“A recent propensity-matched analysis also found that AKI does not increase with SGLT-2 inhibitors [104].”
ResultKrasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · cited 1×
“Incubation of endothelial cells with liraglutide reduced the expression of several inflammatory and pro-inflammatory proteins involved in the atherosclerosis development and progression [154].”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13028 · Cited by 183 · cited 3×
“Gerstein HC, Colhoun HM, Dagenais GR et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.”
BackgroundOrtiz, A., Ziyadeh, F. N., & Neilson, E. G. (1997) · Journal of Investigative Medicine · doi:10.1177/108155899704500207 · Cited by 182
Self-citationWiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.012 · Cited by 181 · cited 1×
“The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure [39].”
BackgroundThe gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181 · cited 1×
“As in the case of every diuretic, the distal tubules are responsible for fine regulation of sodium balance, and most of this sodium is reabsorbed, limiting the overall natriuretic effect [84].”
BackgroundLiu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180
Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy
Sanchez-Niño, M.-D., Bozic, M., Córdoba-Lanús, E., Valcheva, P., Gracia, O., Ibarz, M., Fernandez, E., Navarro-Gonzalez, J. F., Ortiz, A., & Valdivielso, J. M. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00090.2011 · Cited by 171
Self-citationDifferential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166 · cited 1×
“GLP-1 receptor agonists induce an increase in heart rate [182] that theoretically could represent a safety concern [183, 184].”
BackgroundXiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164 · cited 1×
“Proposed mechanisms include reductions in post-prandial chylomicron synthesis and reduced triglyceride absorption [147, 148], as well as increased post-prandial insulin production and reduction in glucagon release leading to inhibition of adipose tissue lipolysis [149, 150].”
BackgroundEmpagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care · doi:10.2337/dc17-1551 · Cited by 162 · cited 1×
“This finding was not present in empagliflozin [107] or dapagliflozin trials [30].”
BackgroundBunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · cited 1×
“This body weight decrease is associated with reduction in total fat, rather than in lean tissue mass [129, 130].”
BackgroundCardiac effects of SGLT2 inhibitors: the sodium hypothesis
Bertero, E., Prates Roma, L., Ameri, P., & Maack, C. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvx149 · Cited by 160
Škrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159 · cited 1×
“An estimated reduction of intraglomerular pressure of 10% or 7– 8 mmHg also occurred [96].”
BackgroundStorgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155 · cited 9×
“Current guidelines for patients with heart failure indicate diuretics to reduce the signs/symptoms of congestion as their effects on mortality have not been studied in large RCTs [52].”
BackgroundInfluentialTashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · cited 1×
“The infusion of liraglutide into apoE / mice significantly retarded atherosclerotic lesions in the aortic wall and suppressed macrophage foam cell formation [152].”
BackgroundDo GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145 · cited 1×
“Early concerns about increased pancreatitis [177, 178] and medullary thyroid cancer risk [177, 179] with GLP-1 receptor agonists have not been substantiated in the large outcome studies [25–27, 115], nor in recent meta-analyses of RCTs [180, 181].”
BackgroundEmpagliflozin’s Fuel Hypothesis: Not so Soon
Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 143 · cited 1×
“Against this hypothesis, it has been argued that the mechanisms of ketone accumulation have not been completely clarified and that in heart failure, the myocardium is already switched to ketone bodies use [70].”
BackgroundFaillie, J.-L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1531 · Cited by 134 · cited 2×
“A similar finding was observed in a large population study with exenatide and liraglutide [176].”
BackgroundResultThe potential for renoprotection with incretin-based drugs
Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 134 · cited 1×
“In addition, pre-clinical studies have shown that GLP-1 receptor agonists reduce proteinuria and glomerular sclerosis associated with protection from endothelial injury and reductions in oxidative stress and inflammation in a glucose-independent manner [168, 169].”
BackgroundTonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126 · cited 1×
“GLP-1 receptor agonists may be able to increase absolute and fractional sodium excretion [143, 144] and may also reduce circulating levels of components of the RAS system [144, 145].”
BackgroundVerma, S., Mazer, C. D., Fitchett, D., Inzucchi, S. E., Pfarr, E., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4644-9 · Cited by 124
Salim, H. M., Fukuda, D., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00043 · Cited by 119
Gilbert, R. E. (2013) · Kidney International · doi:10.1038/ki.2013.451 · Cited by 117 · cited 3×
“However, it was soon postulated to be related to potential nephroprotection [92].”
BackgroundThe effect of liraglutide on renal function: A randomized clinical trial
von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12808 · Cited by 105 · cited 1×
“In small previous studies, liraglutide was associated with reductions in albuminuria around 30%, which were independent of BP or eGFR [162, 163].”
BackgroundInoue, T., Inoguchi, T., Sonoda, N., Hendarto, H., Makimura, H., Sasaki, S., Yokomizo, H., Fujimura, Y., Miura, D., & Takayanagi, R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.026 · Cited by 103 · cited 1×
“Mechanisms beyond these actions may include the natriuretic effects of GLP-1 [138] or a beneficial effect on myocardial cells apoptosis and cardiac fibrosis independently of glucose lowering [160, 161].”
BackgroundJordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., et al. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.07.005 · Cited by 102 · cited 1×
“With regards to sympathetic activation, it is known that diuretic effects are usually associated with reflex-mediated increases in sympathetic tone, whereas caloric loss is associated with decreases; a recent uncontrolled study in 22 patients with type 2 DM showed that empagliflozin treatment did not affect muscle sym…”
ResultBain, S. C., Mosenzon, O., Arechavaleta, R., Bogdański, P., Comlekci, A., Consoli, A., Deerochanawong, C., Dungan, K., Faingold, M. C., Farkouh, M. E., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13553 · Cited by 100 · cited 2×
“The Peptide InnOvatioN for Early DiabEtes Treatment 6 (PIONEER-6) study randomized 3183 patients with type 2 DM and high risk of cardiovascular events to oncedaily oral semaglutide or placebo [119].”
BackgroundBurge, M. R. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.5.1192 · Cited by 96
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Newman, J. D., Vani, A. K., Aleman, J. O., Weintraub, H. S., Berger, J. S., & Schwartzbard, A. Z. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.071 · Cited by 93 · cited 2×
“6% HARMONY OUTCOMES [27]) and are generally considered to be due to improvements in other cardiovascular risk factors including weight, lipids and renal function [112, 113].”
BackgroundDicembrini, I., Nreu, B., Scatena, A., Andreozzi, F., Sesti, G., Mannucci, E., & Monami, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1031-9 · Cited by 92
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Heerspink, H. J. L., & van Raalte, D. H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00030-3 · Cited by 90 · cited 1×
“GLP-1 receptor agonists may be able to increase absolute and fractional sodium excretion [143, 144] and may also reduce circulating levels of components of the RAS system [144, 145].”
BackgroundSarafidis, P. A., Stafylas, P. C., Kanaki, A. I., & Lasaridis, A. N. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.206 · Cited by 87 · cited 2×
“Of note, effects of SGLT-2 inhibitors were additional RAS blockade as 80% of EMPA-REG OUTCOME patients, and a similar percentage of CANVAS patients, were taking ACEis or ARBs at baseline [29, 75].”
ResultSelf-citationSarafidis, P. A., & Ruilope, L. M. (2013) · Kidney International · doi:10.1038/ki.2013.355 · Cited by 81 · cited 3×
“the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopril versus losartan alone [77] were prematurely stopped due to increased risk of complications, including hypotens…”
BackgroundSelf-citationNavarro‐González, J. F., Sánchez-Niño, M. D., Donate‐Correa, J., Martín‐Núñez, E., Ferri, C. M., Pérez‐Delgado, N., Górriz, J. L., Martínez‐Castelao, A., Ortíz, A., & Fernández, C. M. (2018) · Diabetes Care · doi:10.2337/dc18-0078 · Cited by 79
Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78
Nakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., & Nakamoto, T. (2016) · Diabetes Care · doi:10.2337/dc15-1437 · Cited by 77 · cited 1×
“The mechanism for this is currently unknown, but may be mediated by direct actions of these drugs on sinoatrial node [185] or activation of the sympathetic nervous system [186].”
BackgroundTime course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73 · cited 2×
“8 mg/day, which again disappeared after 4 weeks of maximum dose [146].”
BackgroundPiperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M. E., Tsapas, A., & Karagiannis, A. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002050 · Cited by 72 · cited 1×
“These effects of SGLT-2 inhibitors on reduction of glomerular hyperfiltration and intraglomerular pressure are supported by the EMPA-REG OUTCOME and CANVAS trials, as well as several other studies, showing decrease in urine albumin excretion [97, 98].”
ResultSelf-citationvon Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.004 · Cited by 72 · cited 1×
“In small previous studies, liraglutide was associated with reductions in albuminuria around 30%, which were independent of BP or eGFR [162, 163].”
BackgroundImprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71 · cited 3×
“SGLT-2 is a high-capacity/ low-affinity transporter found mainly in the S1-segment, responsible for 90% of glucose reabsorption, while SGLT-1 is a low-capacity/high-affinity transporter in the S2/S3 segment of the PCT, reabsorbing the remaining 10% [20, 81].”
BackgroundSelf-citationon behalf of the EMPA-REG OUTCOME® investigators, Zinman, B., Inzucchi, S. E., Wanner, C., Hehnke, U., George, J. T., Johansen, O. E., & FITCHETT, D. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4630-2 · Cited by 71
Khosla, N., Sarafidis, P. A., & Bakris, G. L. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.06.005 · Cited by 62
Self-citationSGLT1 inhibition: Pros and cons
Tsimihodimos, V., Filippas-Ntekouan, S., & Elisaf, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.019 · Cited by 61 · cited 3×
“Diabetic ketoacidosis (DKA) is a rare but serious complication of SGLT-2 inhibitors for which the FDA issued a warning in 2015 [101].”
BackgroundScheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.008 · Cited by 60 · cited 1×
“inhibitors, suggests that these agents may be preferred to GLP-1 receptor agonists to lower cardiovascular risk [114, 121].”
BackgroundShurter, A., Genter, P., Ouyang, D., & Ipp, E. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.018 · Cited by 57 · cited 1×
“It is possible that the effect of semaglutide on retinopathy in the SUSTAIN-6 trial was due to rapid reduction of blood glucose as reported in other studies [175].”
ResultSudo, M., Li, Y., Hiro, T., Takayama, T., Mitsumata, M., Shiomi, M., Sugitani, M., Matsumoto, T., Hao, H., & Hirayama, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.920 · Cited by 56 · cited 1×
“In rabbits with fully developed atherosclerotic plaques, these agents inhibited plaque growth and modified the plaque components; both macrophage infiltration and calcium deposition were reduced [153].”
BackgroundHirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55 · cited 1×
“In pre-clinical studies, GLP-1 receptor agonists prevented atherosclerosis in non-diabetic mice [151].”
BackgroundRenal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
BETHEL, M. A., MENTZ, R. J., MERRILL, P., BUSE, J. B., CHAN, J. C., GOODMAN, S. G., IQBAL, N., JAKUBONIENE, N., KATONA, B. G., LOKHNYGINA, Y., et al. (2018) · Diabetes · doi:10.2337/db18-522-p · Cited by 54 · cited 1×
“In a recent analysis of opportunistic laboratory data from the EXSCEL study [111], a composite of 40% decline in eGFR, need for renal replacement therapy, renal death and new-onset macroalbuminuria was lower in the exenatide group (HR 0.”
MethodEffect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects
Sancho, V., Trigo, M., Martín-Duce, A., González, N., Acitores, A., Arnés, L., Valverde, I., Malaisse, W., & Villanueva-Peñacarrillo, M. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.6.1133 · Cited by 53 · cited 1×
“Proposed mechanisms include reductions in post-prandial chylomicron synthesis and reduced triglyceride absorption [147, 148], as well as increased post-prandial insulin production and reduction in glucagon release leading to inhibition of adipose tissue lipolysis [149, 150].”
BackgroundSarafidis, P. A., Georgianos, P. I., & Lasaridis, A. N. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903499257 · Cited by 50 · cited 1×
“Side effects of thiazide and loop diuretics, mainly hypokalaemia, were previously suggested to prevent the appearance of the full cardiovascular benefit of these drugs [54, 55].”
BackgroundSelf-citationGaspari, T., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49 · cited 1×
“Mechanisms beyond these actions may include the natriuretic effects of GLP-1 [138] or a beneficial effect on myocardial cells apoptosis and cardiac fibrosis independently of glucose lowering [160, 161].”
BackgroundDo the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 47 · cited 1×
“In addition to the above, direct effects of SGLT-2 inhibitors on cardiomyocytes have been proposed [43].”
BackgroundAn Overview of Errors and Flaws of Estimated GFR versus True GFR in Patients with Diabetes Mellitus
Lima, S. L., & Porrini, E. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000453531 · Cited by 47 · cited 1×
“Interestingly, these differences were not apparent when eGFR was estimated with the creatinine-based CKDEPI formula, which may reflect the error of estimated GFR in the diabetic population [166].”
MethodSelf-citationVlotides, G., & Mertens, P. R. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu299 · Cited by 44 · cited 1×
“Furthermore, this increase in SGLT-2 concentration leads to decreased delivery to the macula densa of sodium and chloride, thus promoting hyperfiltration [91, 92].”
BackgroundBlood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
Sarafidis, P. A., Lazaridis, A. A., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.209 · Cited by 41 · cited 1×
“The impact of BP reduction in these trials was questioned owing to the insignificant effect on the incidence of MI and stroke [49].”
BackgroundSelf-citationSchernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 40 · cited 1×
“Following uncertainty over the cardiovascular safety of rosiglitazone, a peroxisome proliferatoractivated receptor-gamma agonist, about 10 years ago [21], the Food and Drug Administration (FDA) in the USA required all new anti-diabetic agents to have proven non-inferiority compared with standard treatment in major car…”
BackgroundNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Górriz, J. L., Nieto, J., Navarro‐González, J. F., Molina, P., Martínez‐Castelao, A., & Pallardó, L. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4101866 · Cited by 35 · cited 1×
“In diabetic patients, GLP-1-related natriuresis might restore disrupted tubulo-glomerular feedback, resulting in relative vasoconstriction of afferent arteriole leading to decreased glomerular hydraulic pressure [172].”
BackgroundGastrointestinal–Renal Axis: Role in the Regulation of Blood Pressure
Yang, J., José, P. A., & Zeng, C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005536 · Cited by 34 · cited 1×
“GLP-1 receptor agonists may be able to increase absolute and fractional sodium excretion [143, 144] and may also reduce circulating levels of components of the RAS system [144, 145].”
BackgroundGLP-1 receptor agonists and cardiovascular protection: A class effect or not?
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.12.009 · Cited by 32
Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression
Sarafidis, P. A., & Ruilope, L. M. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312439140 · Cited by 24 · cited 1×
“However, many patients with DKD will experience renal and cardiovascular disease progression, despite RAS blockade for various reasons, including uncontrolled blood pressure (BP), use of suboptimal doses of ACEi/ARB due to intolerance and angiotensin-II or aldosterone escape [17].”
BackgroundSelf-citationEffects of incretin-based therapies on renal function
Tsimihodimos, V., & Elisaf, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.049 · Cited by 23 · cited 2×
“Other studies suggested that these agents reduced GFR rate in hyperfiltrating type 2 diabetic patients [138, 170].”
BackgroundBremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 20 · cited 1×
“Under physiological conditions, GLP-1 agonists have either no effect or induce glomerular hyperfiltration by reducing afferent arteriolar resistance [126, 138, 171].”
BackgroundSelf-citationDapagliflozin for the Treatment of Type 2 Diabetes Mellitus
Aylsworth, A., Dean, Z., VanNorman, C., & Okere, A. N. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014540450 · Cited by 18 · cited 1×
“In type 2 DM, the prevalence of obesity or overweight status is estimated at 80%, while some established anti-diabetic therapies cause weight gain [19].”
BackgroundRenal Perfusion and the Renal Hemodynamic Response to Blocking the Renin System in Diabetes
Lansang, M. C., & Hollenberg, N. K. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2025 · Cited by 17
The optimal blood pressure target in diabetes mellitus: a quest coming to an end?
Papadopoulou, E., Angeloudi, E., Karras, S. Ν., & Sarafidis, P. A. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0079-5 · Cited by 17 · cited 1×
“The co-existence of type 2 DM and hypertension has been long established with >90% of patients with type 2 DM being hypertensive [4].”
BackgroundSelf-citationA review of chemical therapies for treating diabetic hypertension
Sarafidis, P. A., Alexandrou, M. E., & Ruilope, L. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328054 · Cited by 16 · cited 1×
“the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopril versus losartan alone [77] were prematurely stopped due to increased risk of complications, including hypotens…”
BackgroundSelf-citationMcHugh, K. R., DeVore, A. D., Mentz, R. J., Edmonston, D. L., Green, J. B., & Hernandez, A. F. (2018) · Clinical Cardiology · doi:10.1002/clc.23054 · Cited by 13 · cited 1×
“6% HARMONY OUTCOMES [27]) and are generally considered to be due to improvements in other cardiovascular risk factors including weight, lipids and renal function [112, 113].”
BackgroundIncretin-based drugs and renoprotection—is hyperfiltration key?
Tonneijck, L., Smits, M. M., van Raalte, D. H., & Muskiet, M. H. A. (2015) · Kidney International · doi:10.1038/ki.2014.398 · Cited by 13 · cited 1×
“The presence of glomerular hyperfiltration might therefore be required for GLP1 receptor agonists to confer reno-protective alterations in renal haemodynamics [173].”
BackgroundHARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
Mafham, M. M., & Preiss, D. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32348-1 · Cited by 9 · cited 2×
“Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) trial NCT03574597] [192].”
BackgroundRenoprotective effects of dulaglutide in patients with T2DM and CKD
Sørensen, C. M., & Holst, J. J. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0055-x · Cited by 7 · cited 1×
“Dulaglitude reduced albuminuria compared with insulin only in the subgroup of patients with microalbuminuria [165, 167].”
BackgroundRyder, B., & DeFronzo, R. A. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.147 · Cited by 6
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationPrevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
Ostrominski, J. W., Arnold, S. V., Butler, J., Fonarow, G. C., Hirsch, J. S., Palli, S. R., Donato, B. M. K., Parrinello, C. M., O’Connell, T., Collins, E. B., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3241 · Cited by 292
Obesity and chronic kidney disease
Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2022 · Cited by 267
Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
Metadata
- Authors
- Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., London, G. M., Massy, Z., Ruggenenti, P., Porrini, E., Wiecek, A., Zoccali, C., Mallamaci, F., & Hornum, M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-01
- Volume
- 34
- Issue
- 2
- Pages
- 208-230
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2914947684
- Cited by
- 204
- References
- 197
- FWCI
- 22.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.